New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy

mesothelioma clinical trial of dendritic cells

A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy »

Patients with Impaired Kidneys Could Still Take Alimta for Mesothelioma, Study Finds

Alimta for mesothelioma is kidney patients

New research in the Netherlands suggests that patients who would not normally be prescribed Alimta for mesothelioma could still benefit from the gold standard mesothelioma treatment. The key is an alternate dosing strategy. Alimta is a powerful drug that works by blocking a molecule needed for cell replication. Right now, doctors do not recommend Alimta for mesothelioma in people with poor kidney function. But Dutch pharmacology experts now say it is possible to adjust the dosing to make Alimta safer for these mesothelioma patients. Alimta for Mesothelioma: Proper Dosing is Key The FDA approved Alimta for mesothelioma in 2004. Alimta (pemetrexed) is still the only drug approved for the treatment of malignant mesothelioma. It has also been approved to treat … Continue reading Patients with Impaired Kidneys Could Still Take Alimta for Mesothelioma, Study Finds »

Quality of Life for Mesothelioma Patients Hinges on Activity and Nutrition

quality of life for mesothelioma

Muscle mass and nutrition can have a direct impact on quality of life for mesothelioma patients. That’s the finding of an Australian study of sixty-one men and women with malignant pleural mesothelioma. Researchers say the quality of life for mesothelioma patients was compromised by lower muscle mass or malnutrition. It is a wake-up call for mesothelioma patients to stay active and eat well for the best outcomes. Impacts on Quality of Life for Mesothelioma Patients Pleural mesothelioma is an incurable cancer. Even with the best mesothelioma treatments, most patients still face a grim prognosis. But there is evidence that good self-care may help. Previous studies have shown that patients with the best nutritional status often have longer mesothelioma survival. Nutritional … Continue reading Quality of Life for Mesothelioma Patients Hinges on Activity and Nutrition »

Chemotherapy During Mesothelioma Surgery: Is it Dangerous?

chemotherapy during mesothelioma surgery

A new study finds that chemotherapy during mesothelioma surgery does not raise the risk for complications. That could be good news for pleural mesothelioma patients who want to keep cancer at bay as long as possible. A group of Indian doctors compared the cases of thoracic cancer patients who had surgery with or without intraoperative chemotherapy. Only one of the “surgery + chemotherapy” patients developed a serious complication. Patients in this group also lived longer than those who did not receive intraoperative chemotherapy. When Do Doctors Use Chemotherapy During Mesothelioma Surgery? The two primary types of mesothelioma surgery are extrapleural pneumonectomy (EPP) or lung-sparing pleurectomy/decortication (P/D). Patients often have chemotherapy prior to surgery to shrink their mesothelioma tumor. Many have … Continue reading Chemotherapy During Mesothelioma Surgery: Is it Dangerous? »

Risk of Dying from Mesothelioma Varies by Type, Study Shows

Risk of dying from mesothelioma

The risk of dying from mesothelioma rises and gradually falls  in the decades after exposure for most, but not all, types of asbestos cancer. New research shows those peaks and valleys can vary based on a number of factors. Public health researchers from across Italy recently published their findings on asbestos workers’ risk of dying from mesothelioma. They suggest that the lifetime risk of dying from peritoneal mesothelioma stays high, even after the risk of death from pleural mesothelioma and lung cancer begins to drop off. Quantifying the Risk of Dying from Mesothelioma Asbestos is the primary cause of all three types of mesothelioma: pleural, peritoneal, and pericardial. Pleural mesothelioma is the most common asbestos-related cancer. Pleural tumors start on … Continue reading Risk of Dying from Mesothelioma Varies by Type, Study Shows »

Conservative Surgery Leads to Better Mesothelioma Survival After Recurrence

mesothelioma survival

Mesothelioma survival after recurrence may be better with lung-preserving P/D surgery than with more radical EPP. Japanese researchers recently analyzed the cases of 44 mesothelioma patients who underwent either EPP or P/D. It took about the same amount of time for mesothelioma tumors to start growing again, no matter what type of surgery the patient had. The difference was in survival. Both overall survival and mesothelioma survival after recurrence were longer in the P/D patients. EPP vs. P/D: The Ongoing Debate Mesothelioma surgeons around the world are still divided about which type of mesothelioma surgery is best. On one hand, extrapleural pneumonectomy (EPP) removes more diseased tissue, including a lung. Some say this improves the odds of long term mesothelioma … Continue reading Conservative Surgery Leads to Better Mesothelioma Survival After Recurrence »

PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma

mesothelioma immunotherapy response

A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have … Continue reading PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma »

Cancer Centers May Not Manage Mesothelioma Symptoms Adequately, Study Finds

manage mesothelioma symptoms

UK researchers say the number of patients receiving palliative care to manage mesothelioma symptoms may be lagging behind the need. Nottingham University conducted a needs assessment of more than 700 patients over two years. Seventy percent of patients with pleural mesothelioma or another thoracic cancer completed a questionnaire shortly after diagnosis. Their results revealed a high unmet need for palliation to manage mesothelioma symptoms and those of other thoracic malignancies. How Does Palliative Care Help Manage Mesothelioma Symptoms? Palliative care is any kind of care that helps patients manage mesothelioma symptoms. These can be physical symptoms like breathing difficulty or fatigue. Or they can be psychological symptoms like fear and worry. Palliative care to manage mesothelioma symptoms can include things … Continue reading Cancer Centers May Not Manage Mesothelioma Symptoms Adequately, Study Finds »

Predicting Thyroid Disease After Immunotherapy for Mesothelioma

thyroid disease after imminotherapy

Researchers in Italy say it is possible to predict which mesothelioma patients are likely to develop thyroid disease after immunotherapy. They are advising their colleagues to use the technique for better management of malignant mesothelioma. Immune checkpoint inhibitors like Keytruda are improving the outlook for people with asbestos cancer. But immunotherapy is not without risk. Certain people are prone to develop thyroid disease after immunotherapy. If doctors know ahead of time which mesothelioma patients are at risk, they can be better prepared to manage problems later.   Immune Checkpoint Inhibitors and Thyroid Disease after Immunotherapy Pleural mesothelioma is extremely difficult to treat. Immune checkpoint inhibitors have given many mesothelioma patients new hope. Recent studies suggest that some of these drugs … Continue reading Predicting Thyroid Disease After Immunotherapy for Mesothelioma »

New Research Reveals Gene Signature for Mesothelioma

gene signature for mesothelioma

Researchers in China say they have come up with a three-gene signature for mesothelioma. The gene signature may help doctors determine mesothelioma prognosis and plan treatment. Pleural mesothelioma is challenging to diagnose and even harder to treat. Many patients do not receive a diagnosis until the disease is in an advanced stage. The new study finds that the gene signature for mesothelioma is “significantly associated”  with overall survival in people with the pleural variety. Testing a Gene Signature for Mesothelioma Genes play an important role in the development and progression of cancers like mesothelioma. The Chinese researchers started by searching for other studies on  mesothelioma prognosis and genes. “The lack of relevant search results indicated that no gene prognostic signatures … Continue reading New Research Reveals Gene Signature for Mesothelioma »

Get your free copy of
“Surviving Mesothelioma” Today!